<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209154</url>
  </required_header>
  <id_info>
    <org_study_id>2017/6534</org_study_id>
    <nct_id>NCT03209154</nct_id>
  </id_info>
  <brief_title>An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment</brief_title>
  <acronym>IDA</acronym>
  <official_title>Individualized Blood Pressure Treatment: a Multidisciplinary Approach to Uncontrolled Hypertension in Order to Reduce Morbidity and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate and explore the most important aspects of
      drug-adherence in the treatment of hypertension in order to improve treatment and blood
      pressure control, implying that new knowledge will reduce morbidity and mortality.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>3 months after baseline</time_frame>
    <description>Change in systolic daytime ambulatory blood pressure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Uncontrolled Hypertension</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Group intervention: Therapeutic drug monitoring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Therapeutic drug monitoring</intervention_name>
    <description>Therapeutic drug monitoring will be performed.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Home blood pressure monitoring</intervention_name>
    <description>Patients will perform home blood pressure monitoring at home.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Uncontrolled hypertension

          -  A stable medication regimen for at least 4 weeks of ≥ 2 antihypertensive agents

          -  No planned changes in antihypertensive drugs

        Exclusion Criteria:

          -  Withdrawal of consent

          -  Patients with inadequate Norwegian language skills

          -  Positive pregnancy test

          -  Known alcohol or drug abuse

          -  estimated glomerular filtration rate &lt;30 mL/min/1.73m2

          -  Albumin/creatinin ratio &gt;300 mg/mmol

          -  Any reason why, in the opinion of the investigator, the patient should not participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sverre E Kjeldsen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla L Søraas, MD PhD</last_name>
    <phone>+4722119100</phone>
    <email>camillalare@yahoo.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sverre E Kjeldsen, MD PhD</last_name>
    <phone>+4722119100</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla L Søraas, PhD</last_name>
      <phone>+4799566088</phone>
      <email>uxamlu@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Ulla P Hjørnholm, MSc</last_name>
      <phone>+4722199338</phone>
      <email>ullhjo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ola U Bergland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lene V Halvorsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Sverre Erik Kjeldsen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>Therapeutic Drug Monitoring</keyword>
  <keyword>Patient perspective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

